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Abstract 
Immune enhancement is desirable in situations where decreased immunity results in 
increased morbidity. We investigated whether blocking the surface inhibitory receptor 
PD-1 and/or p38 MAP kinase could enhance the proliferation of the effector memory 
CD8+ T-cell subset that re-expresses CD45RA (EMRA) and exhibits characteristics 
of senescence, which include decreased proliferation and telomerase activity but 
increased expression of the DNA damage response-related protein H2AX. Blocking 
of both PD-1 and p38 MAPK signalling in these cells enhanced proliferation and the 
increase was additive when both pathways were inhibited simultaneously in both 
young and old human subjects. In contrast, telomerase activity in EMRA CD8+ T 
cells was only enhanced by blocking the p38 but not the PD-1 signalling pathway, 
further indicating that non-overlapping signalling pathways were involved. Although 
blocking p38 MAPK inhibits TNF- secretion in the EMRA population, this decrease 
was counteracted by the simultaneous inhibition of PD-1 signalling in these cells. 
Therefore, end-stage characteristics of EMRA CD8+ T cells are stringently controlled 
by distinct and reversible cell signalling events. In addition, the inhibition of PD-1 and 
p38 signalling pathways together may enable the enhancement of proliferation of 
EMRA CD8+ T cells without compromising their capacity for cytokine secretion.  
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Introduction 
Human T-cell memory is maintained by episodes of repeated antigenic challenge 
throughout life [1, 2]. These antigenic encounters drive proliferation and 
differentiation of memory T cells, leading to the accumulation of highly differentiated 
T cells in older subjects [1, 3]. Highly differentiated T cells also accumulate in 
patients with malignancy [4] and those with persistent infections [3, 5, 6]. However, 
highly differentiated CD4+ and CD8+ T cells in humans have decreased proliferative 
capacity [7-9]. Therefore it is possible that the increased susceptibility to infections 
and malignancy during ageing may result from suboptimal maintenance of 
responsive pools of specific T cells due to their dysfunctional ability to divide [10, 11]. 
This raises the question of whether it is possible to enhance T-cell proliferation in 
older subjects.  
 
Human T cells at late stages of differentiation can be identified by the loss of surface 
markers CD27, CD28 and CCR7 and the re-expression of CD45RA [7, 9, 12]. 
Furthermore highly differentiated memory T cells have relatively short telomeres [13] 
and have changes in cell signalling pathways including defective Akt/PKB [7, 12] and 
increased p38 MAP kinase (MAPK) phosphorylation that are associated with cellular 
senescence [7, 9, 12, 14]. These changes are particularly evident in highly 
differentiated effector memory T cells that re-express CD45RA (EMRA T cells) [7, 
12] which are considered to be an end-stage or senescent population [15, 16]. The 
EMRA CD4+ and CD8+ T cells also exhibit the loss of both proliferative capacity and 
telomerase activity and have increased susceptibility to apoptosis [7, 9, 12, 17] and 
these cells increase significantly during ageing.  
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Two processes have been shown to induce a loss of proliferative ability in T cells. 
First, repeated antigenic stimulation of T cells may induce a state of functional 
exhaustion where proliferative activity and cytokine production are lost [18]. This 
immune exhaustion is initiated by external cell surface inhibitory receptors such as 
PD-1 and Tim3 [19, 20]. Second, repeated T-cell stimulation or genotoxic damage by 
agents such as reactive oxygen species can induce replicative senescence where 
cells lose proliferative potential [1, 8]. This process is triggered by a DNA damage 
response (DDR) that leads to growth arrest if the DDR is not resolved [21, 22]. It is 
not clear if  senescence and exhaustion signaling pathways are distinct processes 
[14] or if they act in isolation or in concert to control the proliferation of end-stage or 
senescent CD8+ T cells.    
 
We now demonstrate that the proliferation of highly differentiated EMRA CD8+ T 
cells can be enhanced in an additive manner by blocking p38 MAPK and PD-1 
signalling together, however, other functions such as telomerase activity are uniquely 
regulated by the p38 MAPK pathway. Furthermore, by inhibiting both pathways 
simultaneously, highly differentiated T cells can be induced to exhibit increased 
proliferative potential while also retaining their ability to secrete cytokines such as 
TNF- that cannot be achieved by blocking either pathway alone. Nevertheless in 
old individuals, other mechanisms controlling proliferation may exist, since the 
proliferative activity of EMRA CD8+ T cells after blockade of PD-1 and p38 MAPK 
signalling does not restore proliferative responses to the level observed in young 
subjects. 
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Results 
CD8+ EMRA T cells from young and old donors exhibit characteristics of 
senescent T cells  
Human CD8+ T cells can be subdivided into 4 populations on the basis of their 
relative surface expression of CD45RA and CD27 molecules (Fig. 1A). Four subsets 
can be defined, naïve (N; CD45RA+CD27+), central memory (CM; CD45RA-CD27+) 
effector memory (EM; CD45RA-CD27-) and effector memory T cells that re-express 
CD45RA (EMRA; CD45RA+CD27-). We have previously shown that the EMRA 
population, when isolated from young individuals exhibited senescent characteristics 
[8], we now extend this to CD8+ T cells from old individuals. Using a panel of 
antibodies that defines senescent characteristics, KLRG1, CD57 and H2AX 
(Fig.1A), we find that upon overnight stimulation the CD8+ T-cell subsets isolated 
from old individuals express a greater array of senescent markers relative to young 
individuals (Fig. 1B). Furthermore, the EMRA population from old donors have more 
senescence characteristics than those isolated from young donors (Fig. 1C). 
However what is also evident is that differential expression of senescent features 
between the subsets follows a similar pattern in both young and old donors, 
therefore the higher levels of senescent characteristics observed are dependent on 
age.  
 
A lack of proliferation is a defining feature of senescence [8]. We found that when 
using Ki67 staining as a readout for proliferation CD8+ EMRAs, from both young and 
old individuals, exhibit a significant proliferative impairment when compared to the 
less differentiated subsets after stimulation (Fig 2A). This was not thought to be 
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caused by a lower expression of CD3 in this subsets, as we have previously 
published it to be elevated [23]. However, the proliferative activity in all four subsets, 
especially in the naive and EMRA populations, was decreased in the old volunteers 
(Fig. 2A).  In addition we found that there was a significant reduction in telomerase in 
the EMRA population from young and old individuals when compared to the other 
three subsets (Fig 2B). Again the amount of telomerase activity detected in all the 
CD8+ subsets isolated from old donors was significantly less than the levels seen in 
young donors (Fig. 2C) which supports our previous observation that old individuals 
have shorter telomere lengths in all these subsets compared to the young cohort 
[24].  
 
Despite the EMRA population of CD8+ T cells having less proliferative and 
telomerase activity, these cells, when isolated from both young and old donors, were 
significantly more multifunctional than the other subsets, defined by using a panel 
that measured the expression of perforin, granzyme B, IFN- and TNF-α 
simultaneously (Fig. 3A and B). It is interesting to note that the naïve CD8+ T cells 
isolated from old donors display considerably more polyfunctionality than the CM 
cells (Fig. 3B), suggesting that naïve cells isolated from old donors, identified by 
CD45RA+CD27+ expression may not be a truly naïve population. However CD8+ EM 
cells from young donors were found to be more polyfunctional based on 4 functions 
relative to older donors (Fig. 3B). 
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We next investigated each cellular function separately in each of the subsets of 
young and old donors (Fig. 3C). We found that the despite their senescence 
characteristics, the percentage of the CD8+ EMRA T-cell population in both age 
groups expressed high levels of pro-inflammatory cytokines and cytotoxic molecules. 
However while these cells from old donors expressed a higher percentage of 
cytokines, they exhibited lower levels of perforin and granzyme B after stimulation. 
Once again, a striking observation was that the naïve CD45RA+CD27+ population 
showed greater capacity for both cytokine secretion and cytotoxicity than their 
counterparts in young subjects reinforcing the possibility that these cells in old 
donors are not truly naïve. 
 
Expression of PD-1 and p38 MAPK during CD8+ T-cell differentiation 
We next investigate mechanisms that were involved in inhibiting proliferation in 
donors form both age groups. PD-1 is the most investigated inhibitory receptor that is 
expressed by exhausted CD8+ T cells [25]. When we examined the expression of 
PD-1 on CD45RA/CD27 defined CD8+ T-cell subsets, we found the highest level of 
expression to be on the CM and EM subsets (Fig. 4A and B). These results together 
with their high functionality indicate that the CD8+ EMRA subset in young and old 
subjects is not an exhausted population. 
 
Increased expression of p38 MAPK is associated with senescent T cells [26]. We 
found that naïve T cells express the lowest levels and EMRA T cells express 
significantly higher amounts of phosphorylated p38 MAPK ex vivo (Fig. 4C and D). 
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This supports the concept that EMRA CD8+ T cells are an end-stage/senescent 
population 
 
Both PD-1 and p38 MAPK signalling contribute to reduced proliferation of 
EMRA T cells 
We next investigated whether either PD-1 or p38 MAPK signalling pathways 
contribute to the decreased proliferative activity of EMRA CD8+ T cells. We isolated 
the four CD45RA/CD27 defined T-cell subsets from both young and old donors, 
which were stimulated with anti-CD3 antibody and irradiated autologous APCs in the 
presence of either PDL1/2 blocking antibodies, BIRB 796 or both inhibitors together. 
Proliferative activity was determined by staining with Ki67 antibody. Representative 
histograms for the EMRA subset with and without the inhibitors from young and old 
donors are shown in Figures 5A and C, respectively. The cumulative data from 9 
young and 5 old donors are shown in Figures 5B and D, respectively. In young 
donors, inhibiting PD-1 signalling increased proliferative activity in CD8+ T cells at all 
four stages of differentiation. However, the inhibition of the p38 MAPK pathway was 
only effective at increasing proliferation in the end-stage EMRA subset (Fig. 5A and 
B). There was additive enhancement of proliferation in the EMRA subset when both 
signalling pathways were inhibited together (Fig. 5A and B). When we investigated 
the old group, PD-1 blockade significantly enhanced the proliferation of EM and 
EMRA subsets only (Fig 5C and D). In contrast, blockade of p38 MAPK was found to 
increase the proliferative capacity of both the naïve and EMRA subsets (Fig. 5D). 
Once again there was an additive enhancement in the EMRA subset when both 
signalling pathways were inhibited together (Fig. 5C and D).  
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We have recently published that while the EMRA population secretes high levels of 
cytokines in response to TCR stimulation, their response to CMV-specific stimulation 
is blunted [23]. We therefore decided to investigate the effect of PD-1 and p38 MAPK 
blockade in response to antigen-specific stimulation (Fig. 6). The proliferative 
response, measured by Ki67 of sorted CMVpp65-specific CD8+ CD45RA/CD27 T-
cell subsets to the peptide NLV in young (n = 5) and old (n = 4) individuals followed a 
similar trend to that seen when using anti-CD3 (Fig. 5). Following treatment the most 
responsive subsets to blockade were the EMRAs in both the young (Fig. 6A and B) 
and old (Fig. 6B and D) donors. An additive enhancement was again observed when 
both blocks were used together (Fig 6B and D).  
Signalling through p38 MAPK but not PD-1 pathways reduces telomerase 
activity of EMRA T cells 
We next investigated whether p38 MAPK or PD-1 signalling were involved in the 
decreased telomerase activity in EMRA CD8+ T cells isolated from young old 
individuals. Our previous data indicated that p38 MAPK signalling inhibits telomerase 
activity in both CD4+ [12] and CD8+ [8, 27] EMRA T cells in young individuals. We 
stimulated CD8+ T-cell subsets with anti-CD3 and irradiated autologous APCs in the 
presence of both inhibitors separately or together as described previously. We found 
that incubation with BIRB 796 caused a significant increase in telomerase activity in 
the EMRA population isolated from young individuals, either when added alone or 
with anti-PDL-1/2 (Fig. 7A and B). When we examined CD8+ EMRA T cells from old 
individuals we found that p38 MAPK inhibition also increased telomerase activity, 
however the level of enzyme activity was not increased to the levels observed in 
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young subjects (Fig. 7C). Therefore, additional mechanisms may be involved in the 
reduced telomerase activity in these cells during ageing. 
 
p38 MAPK signalling inhibits TNF- secretion; blocking PD-1 reverts this effect 
in CD8+ T cells  
Previous studies have shown that p38 MAPK signalling plays an essential role in the 
production of TNF-in T cells [28]. The EM and EMRA CD8+ T cells from young 
donors (Fig. 8) secreted the highest levels of this cytokine after activation. As 
described above, both the naïve and EMRA population from old donors secreted 
high levels of TNF-. PD-1 blockade had no effect on TNF- secretion in any of the 
subsets in both age groups. In contrast, the inhibition of p38 MAPK signalling 
significantly inhibited the secretion of TNF-in all four subsets in both young and old 
individuals (Fig. 8 A and B). However when p38 MAPK and PD-1 were inhibited 
together, the capacity for TNF- secretion was restored in the EMRA CD8+ T cells in 
young and old donors. We found that blocking PD-1 or p38 MAPK individually or 
together had no consistent effect on IFN-, perforin or Granzyme B. Therefore the 
simultaneous blockade of p38 and PD-1 signalling pathways together restores 
proliferation and telomerase activity and also maintains the capacity for TNF-
production from EMRA of CD8+ T cells in young and old subjects. This cannot be 
achieved with blocking either molecule alone.  
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Discussion 
Our main observation is that the CD8+ EMRA T-cell population is a potent effector 
subset that has its replicative potential and survival capacity that is rigidly controlled 
by non-overlapping senescence- and exhaustion-related signalling pathways. The 
simultaneous targeting of both the p38 MAPK (senescence) and PD-1 (exhaustion) 
pathways enhances their proliferative responses, to both polyclonal and antigen-
specific stimuli, while allowing the retention of effector capacity. This may be of 
benefit during vaccination where a low proliferative potential has been shown to 
reduce the effectiveness of therapeutic vaccination [29]. 
 
Both p38 MAPK and PD1 have been the focus of much pharmaceutical interest, with 
therapies targeting the PD-1/PD-L1 axis being effective in the treatment of 
melanoma, renal carcinoma and non-small cell lung cancer [30]. However while 
treatment is generally well tolerated, a spectrum of immune-related adverse events 
have been experienced [30]. Furthermore, not all patients respond to PD-1/PD-L1 
therapy [31]. p38 MAPK is critically involved in the induction of pro-inflammatory 
cytokine secretion, many pharmaceutical companies have p38 MAPK inhibitors in 
phase II and phase III clinical trials for the treatment of several inflammatory 
disorders [32-34]. However these drugs have been limited by their therapeutic index 
and a requirement for TNF- to generate cytotoxic T cells. We show here that when 
p38 MAPK and PD-1 were inhibited together they were able to restore the capacity 
for TNF- secretion in the EMRA subset, presumably owing to an unmasking of the 
enhancing effect on TNF- secretion when using PD-1 blockade alone. We suggest 
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that p38 inhibitors could also be used for immune enhancement, providing that PD-1 
signalling is inhibited at the same time.  
 
The greatest functional effect of simultaneous PD-1 and p38 MAPK inhibition was 
observed in the CD8+ T-cell EMRA subset, where p38 MAPK is maximally expressed 
but PD-1 is not. However, differing PD-1 expression levels may engage distinct 
intracellular targets [35]. For example, PD-1 binds the SH2 domain-containing 
protein tyrosine phosphatases SHP-1 and SHP-2 in naïve T cells, but in exhausted 
cells the very high levels of PD-1 expression can recruit additional signalling 
molecules [35]. The varying levels of expression of PD-1 by CD8+ T cells that are at 
different stages of differentiation have implications for anti-viral therapy. For 
example, Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV) and 
cytomegalovirus (CMV) specific CD8+ T-cell populations are predominantly 
comprised of cells at early, intermediate and late differentiation stages respectively 
[3] and these specific cells may therefore be differentially affects by PD-1 blockade . 
 
The augmented levels of DNA damage observed in EMRAs may be a consequence 
of their highly impaired telomerase expression since telomerase can protect T cells 
against oxidative stress [36] in addition to telomere erosion and this enzyme is a 
critical regulator of the DDR [37]. p38 MAPK is activated in response to DNA 
damage and indeed, its expression in different CD8+ T-cell subsets correlates with 
the phosphorylation of H2AX, a component of DNA damage foci. Although p38 
MAPK signalling has a central role in inducing senescence that results in apoptosis 
of the cells [7], it is also involved in pro-inflammatory cytokine production by CD4+ 
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and CD8+ T cells including IFN-γ and TNF-α production [38]. This suggests that p38 
MAPK signalling may be a key component that regulates the development of typical 
effector cell characteristics such as susceptibility to death but potent functional 
capacity. 
 
Also evident from this study is that naïve cells isolated on the basis of cell phenotype 
from old individuals are not truly naïve. Unprimed naive cells are characterized by 
the absence of cytotoxic factors [39], however aged “naïve cells” express significant 
amounts of granzyme, perforin, TNF-α and IFN-, and have short telomeres 
compared to cells from young individuals [24]. We hypothesise that these cells have 
undergone antigen-independent homeostatic expansion to convert to a functional 
state similar to that of memory T cells [7, 23, 40], which raises the question about the 
use of phenotypic markers to analyse functional outcomes from a heterogeneous 
population. We also found that CD8+ EMRA T cells from old donors, while 
expressing increased levels of TNF-α and IFN-, display significantly reduced levels 
of perforin and granzyme. This loss of cytotoxic killing apparatus by senescent T 
cells may contribute to their ineffective immune responses to viruses, which has 
been observed in HIV infection  [41]. We speculate that the reduced expression of 
cytotoxic molecules in CD8+ EMRA T cells from old donors may be due to a 
decreased production and/or responsiveness to IL-2 [42-44],  that has been shown 
to increase the expression of perforin and granzyme and enhance cytolytic function 
[45]. Alternatively the higher frequency of lytic molecules produced by CD8+ EMRA T 
cells of young individuals could reflect faster immunological control the young. 
Epigenetic mechanisms alter chromatin structure and influence gene expression, 
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indeed the epigenetic control of granzyme B during CD8+ T-cell differentiation has 
recently been demonstrated [46].  They showed an increased susceptibility to 
nuclease digestion in the chromatin dense proximal region of the gzmB promoter, 
suggesting that gzmB transcription is mediated by manipulating the accessibility of 
the transcriptional machinery to the promoter [46].  Given that DNA damage and 
inflammation are both capable of altering chromatin structure [47] it is conceivable 
that the epigenetic control of cytokine release is less flexible in old individuals. It is 
also of note that while the simultaneous blockade of PD-1 and p38 MAP kinase 
signaling in CD8+ EMRA T cells from old individuals has similar effects on enhancing 
functional responses as observed in young subjects, the reconstituted functional 
responses are still lower than in the young group. This suggests that there are 
additional defects in the functional responses in the old group that may not be 
regulated by PD-1 and p38 MAPK signaling.  
 
In addition to PD-1, there is a diverse array of other cell surface inhibitory molecules 
that can regulate T-cell exhaustion and gene expression profiles have identified that 
exhausted CD8+ T cells co-express up to seven inhibitory receptors [25, 48]. While 
PD-1 signalling is induced by cell surface interactions, p38 MAPK signalling is 
induced by intracellular DNA-damage associated signalling processes [14]. An 
exciting prospect for the future is that it may be possible to target different receptors 
or downstream components of exhaustion and senescence pathways to custom 
design a tailored T-cell response that is appropriate for a particular situation. 
 
  
 
 
 
 
This article is protected by copyright. All rights reserved.   15 
 
It is possible that blocking PD-1 and/or p38 MAPK may enhance the function of 
these cells in older humans [49] or patients with skin malignancy [19, 20]. However 
this raises the question of whether it is safe to do so. Whereas senescence may 
have a role in preventing malignancy, exhaustion may reduce the risk of 
immunopathology that results from excessive immune activation [14]. Therefore the 
reversal of T-cell senescence by p38 MAPK blockade carries a risk of malignant 
transformation of these cells while reversing the process of exhaustion may lead to 
excessive T-cell activity that leads to tissue damage [14]. However, while long-term 
blockade of p38 and or PD-1 signalling has associated risks, the short-term blockade 
of these signalling pathways may temporarily enhance immunity. This would be 
beneficial in older humans who have decreased immunity and in patients with 
cancer. These possibilities have to be investigated further to clarify whether it is 
feasible to use new strategies involving the blockade of both PD-1 and p38 MAPK to 
boost immunity in these subjects.  
Materials and Methods 
Blood sample collection and isolation 
Heparinised peripheral blood samples were collected from young and old healthy 
donors (Young age range: 20-35, median 32 years, n= 33; old age range: 65-82, 
median 72 years, n= 31). Healthy was taken as donors who had not had an infection 
or immunisation within the last month, no known immunodeficiency or any history of 
chemotherapy or radiotherapy, and were not receiving systemic steroids within the 
last month or any other immunosuppressive medications within the last 6 months. All 
samples were obtained in accordance with the ethical committee of Royal Free and 
University College Medical School. PBMC were isolated using Ficoll hypaque [50]. 
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Flow cytometric analysis and cell sorting 
Flow cytometric analysis was carried out using the following antibodies: Live/dead 
fixable blue dead cell stain (Invitrogen), KLRG1 PE (2F1/KLRG1), PD-1 PE 
(EH12.2H7) and CD45RA Brilliant Violet 605 from Biolegend. CD8 PerCP (SK1), 
CD8 Alexa Fluor 700 (RPA-T8), CD27 V500 (M-T271), CD27 allophycocyanin (M-
T271), CD27 allophycocyanin -H7 (M-T271), CD45RA PE-Cy7 (L48), CD57 
allophycocyanin (NK-1), from BD Biosciences. For intracellular staining the following 
antibodies were used: IFN- V450 (B27), granzyme B Alexa Fluor 700 (GB11), TNF-
 PE (MAb11), perforin FITC (G9) and p38 Alexa Fluor 488 (36/p38) all from BD 
Biosciences. For intranuclear staining: H2AX Alexa Fluor 488 (2F3, Biolegend) and 
Ki67 FITC (B56; BD Biosicences). Samples were processed using an LSR II (BD 
Biosciences) and analysed using FlowJo software (Treestar).  
 
CD8+ T cells were isolated by positive selection using the VARIOMACS system 
(MiltenyiBiotec) according to the manufacturer’s instructions. Positively selected 
CD8+ T cells were labeled with CD27 FITC (M-T271) and CD45RA allophycocyanin 
(HI100; BD Biosciences) and sorted using a FACSAria (BD Biosciences). 
Multiparamter flow cytometry was performed using SPICE version 5.2, downloaded 
from http://exon.niaid.nih.gov [51]. 
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Phospho-cytometry 
The level of p38 (pT180/pY182) was analysed ex vivo using the surface markers; 
CD45RA BV610, CD27 V500 and CD8 AF700, PBMCs were fixed with warm Cytofix 
Buffer (BD Biosciences) at 37°C for 10 min. Cells were permeabilised with ice-cold 
Perm Buffer III (BD Biosciences) at 4°C for 30 min and incubated with the anti-p38 
antibody (pT180/pY182) for 30 min at room temperature. γH2AX (pSer139) was 
detected in sorted subsets following activation with 0.5 g/ml plate coated anti-CD3 
and 5 ng/ml of rhIL-2 for 4 days, after which time the above method was used. 
Proliferation assays  
CD45RA/CD27 purified CD8+ T cells were stimulated with 0.5µg/ml plate coated anti-
CD3 (OKT3) and irradiated APCs, as a source of co-stimulation, proliferation was 
assessed by staining for the cell cycle related nuclear antigen Ki67 after 4 days [50]. 
Irradiated APCs consisted of the remaining PBMC fraction minus the sorted 
population of interest.  
Proliferation in response to CMV-specific stimulation was achieved through a 4 day 
incubation of PBMCs with 0.2 µg/ml NLVPMVATV peptide (ProImmune), after which 
time the cells were stained with Ki67 as detailed above.  
Measurement of telomerase activity 
Isolated CD8+ T-cell populations (2 x 105 cells) were snap-frozen after stimulation. 
Telomerase activity was determined using the TRAPeze telomerase detection kit 
and the TRAPeze ELISA Telomerase Detection Kit (Chemicon) according to the 
protocol provided by the manufacturer. The absolute numbers of CD8+ T cells were 
calculated using trypan blue (Sigma). The TRAP assay was performed with samples 
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adjusted to 500 Ki67+ T cells per reaction to control for the different level of 
proliferation in the subsets following activation [50]. 
 
PDL-1/2 blockade and p38 MAPK inhibitor 
CD8+ and sorted subsets CD27/CD45RA was blocked by adding 10 g/ml each of 
anti-PD-L1 (29E.2A3.C6) and anti-PD-L2 (24F.10C12.G12, both from Biolegend), or 
10 g/ml each of IgG2a (Mg2a-53) or IgG2b (MPC-11) isotype control antibodies 
(Abcam) for 4 day stimulated with anti-CD3 (purified OKT3, 0.5 g/ml) and irradiated 
APCs or with 0.2 µg/ml NLVPMVATV peptide (ProImmune). The p38 inhibitor 
BIRB796 (Selleck Chemicals) was added to the 4 day cultures at a final 
concentration of 500nM [8, 12] using 0.1% DMSO as a control.   
 
Measurement of TNF- following inhibition 
Different CD45RA/CD27 defined CD8+ T-cell subsets were sorted and 2 x105 cells 
were cultured with 0.5 µg/ml plate coated anti-CD3 (OKT3) and 5ng/ml rhIL-2, with or 
without anti-PDL1/2 and BIRB796. Culture supernatants were collected at 48 h for 
the measurement of TNF-α using the Quantikine human TNF- immunoassay (R&D 
Systems) according to the protocol provided by the manufacturer. 
 
Statistical analysis  
Graphpad Prism was used to perform statistical analysis. Statistical significance was 
evaluated using a repeated measures ANOVA with the Tukey correction used for 
post-hoc testing. Differences were considered significant when P was < 0.05. 
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Figure 1. CD8+ EMRA cells exhibit characteristics of senescent T cells.  
(A) CD8+CD45RA+CD27- T cells isolated from young and old individuals were 
isolated and stained for KLRG1, CD57 and γH2AX and analysed by flow cytometry. 
One representative plot out of eight is shown. (B) Expression of senescence 
markers, KLRG1, CD57 and H2AX, in CD8+ CD45RA/CD27 T-cell subsets ex-vivo 
was analysed by multiparameter flow cytometry T-cell. Pie charts show the average 
distribution of cells showing 0, 1, 2 or 3 senescent functions within each subset from 
8 young and 8 old donors. (C) Percentage of CD8+ T-cell subsets (N; naïve, 
CD45RA+CD27+; CM, central memory, CD45RA-CD27+; EM, effector memory, 
CD45RA-CD27- and EMRA, effector memory T cells that re-express CD45RA, 
CD45RA+CD27-) expressing 3 senescent features in cells isolated from young and 
old individuals generated using SPICE version 5.2, downloaded from 
http://exon.niaid.nih.gov. The graph shows the mean  SEM for 8 young (dark green) 
and old donors (light green) and P values were calculated using a repeated 
measures ANOVA with the Tukey correction used for post-hoc testing. *p < 0.05. 
  
 
 
 
 
This article is protected by copyright. All rights reserved.   24 
 
 
 
  
 
 
 
 
This article is protected by copyright. All rights reserved.   25 
 
Figure 2. CD8+ EMRA cells display functional characteristics of senescence.  
(A) Proliferation of CD45RA/CD27 subsets from young and old donors was assessed 
by Ki67 staining following stimulation with 0.5 g/ml anti-CD3 and irradiated APCs 
for 4 days. Each symbol represents a single donor, horizontal lines depict mean 
values. (B and C) Telomerase activity in CD8+ CD45RA/CD27 subsets from young 
and old donors was measured following a 4 day incubation with 0.5 µg/ml anti-CD3 
and irradiated APCs, using the TRAPeze telomerase detection kit. (B) One 
representative gel is shown. (C) Graph showing the percentage expression of  the 
mean  SEM of relative telomerase activity, calculated as the intensity of signal 
corresponding to the TRAP product ladder bands compared to the internal standard 
(IS), from 4 young and 4 old donors. All P values were calculated using a repeated 
measures ANOVA with the Tukey correction used for post-hoc testing. *p < 0.05, **p 
< 0.01, ***p < 0.005. 
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Figure 3. CD8+ EMRA cells retain effector function.  
(A) CD8+CD45RA+CD27- T cells isolated from young and old individuals were 
stained for TNF-α, IFN-, perforin and granzyme B and analysed by flow cytometry. 
One representative plot out eight is shown. (B) Expression of IFN-, TNF-, perforin 
and granzyme B in CD8+ CD45RA/CD27 T-cell subsets following 8 h-stimulation with 
0.5 µg/ml anti-CD3 was analysed by multiparameter flow cytometry. Pie charts show 
the average distribution of cells showing 0, 1, 2, 3 or 4 effector functions within each 
subset from 8 young and old donors. (C) Percentage of CD8+ T-cell subsets 
expressing TNF-, IFN-, perforin and granzyme B. The graphs show the mean  
SEM for 8 young (black) and 8 old donors (grey) and P values were calculated using 
a repeated measures ANOVA with the Tukey’s correction used for post-hoc testing. 
*p < 0.05, **p < 0.01, ***p < 0.005. 
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Figure 4. Expression of PD-1 and p38 MAPK during CD8+ T-cell differentiation.  
(A and B) PD-1 expression on CD8+ CD45RA/CD27 defined T-cell subsets from 
young and old donors was measured by flow cytometry. (A) One representative plot 
out of 19 young and 15 old donors is shown. (B) Each symbol represents a single 
donor, horizontal lines depict mean values. (C and D) Phosphorylated p38 MAPK in 
young and old CD8+ CD45RA/CD27 defined T-cell subsets examined directly ex vivo 
by flow cytometery. (C) One representative plot out of 9 young and 9 old donors is 
shown. (D) Graph shows mean  SE of phosphorylated p38, normalised in relation to 
the CD45RA+CD27+ subset, for 9 young and 9 old donors. All P values were 
calculated using a repeated measures ANOVA with the Tukey correction used for 
post-hoc testing.  *p < 0.05, **p < 0.01, ***p < 0.005. 
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Figure 5. Signalling through both PD-1 and p38 MAPK pathways contributes to 
reduced proliferation the of CD8+ EMRA T cells.  
(A and C) Representative example of Ki67 staining on CD45RA+CD27- T cells 
measured  by flow cytometry after 4 days stimulation with 0.5 µg/ml anti-CD3 and 
irradiated autologous mononuclear cells from young (A) and old (C) donors. This 
activation was performed in the presence of 10 g/ml anti-PDL1/2 antibodies or 500 
nM BIRB796. In control cultures, 10 g/ml IgG2a, IgG2b or 0.1% DMS0 were added 
individually or together. (B and D) Pooled data showing the effect of inhibition on 
proliferation, measured by Ki67, in CD8+ CD45RA/CD27 T-cell subsets that were 
activated as above in young (B) and old (D) donors. Graphs show the mean  SE for 
single measurements of 4 young and 4 old donors and P values were calculated a 
repeated measures ANOVA with the Tukey correction used for post-hoc testing.  *p 
< 0.05, **p < 0.01. 
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Figure 6. PD-1 and p38 MAPK signalling pathways contribute to decreased 
proliferation the of CMV-specific CD8+ EMRA T cells.  
(A and C) Flow cytometry gating and representative example of Ki67 staining for 
CMVpp65-specific CD8+ CD45RA/CD27 T-cell subsets measured after 4 days 
stimulation with 0.2 µg/ml NLVPMVATV peptide from young (A) and old (C) donors. 
Stimulation was performed in the presence of 10 g/ml anti-PDL1/2 antibodies or 
500 nM BIRB796. In control cultures, 10 g/ml IgG2a, IgG2b or 0.1% DMS0 were 
added individually or together. (B and D) Pooled data showing the effect of inhibition 
on proliferation, measured by Ki67, in sorted CMVpp65-specific CD8+ 
CD45RA/CD27 T-cell subsets stimulated as above in young (B) and old (D) donors. 
Graphs show the mean  SEM pooled from 5 young and 4 old donors and P values 
were calculated by repeated measures ANOVA with the Tukey correction used for 
post-hoc testing.  *p < 0.05, **p < 0.01. 
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Figure 7. Signalling through p38 MAPK but not PD-1 pathways regulates 
reduced telomerase activity of CD8+ EMRA T cells.  
(A) Representative blot for telomerase activity in CD8+ CD45RA/CD27 T-cell subsets 
on day 4 following activation with 0.5 g/ml anti-CD3 and irradiated autologous 
APCs, 10 g/ml anti-PDL1/2, 500 nM BIRB 796 or both molecules, using the 
TRAPeze and TRAPeze ELISA telomerase detection kit. The blot is representative 
of 4 separate experiments. (B) Telomerase activity from young donors was analysed 
as described above. The graph shows the mean  SEM pooled from 4 donors. (C) 
CD8+ CD45RA/CD27 T-cell subsets from young and old donors following 4 day 
incubation with 0.5 g/ml anti-CD3 and irradiated autologous APCs with or without 
500 nM BIRB 796 were analysed by TRAPeze T-cell ELISA. The graph shows the 
mean + SE for single measurements from 5 donors and all P values were calculated 
using a repeated measures ANOVA with the Tukey correction used for post-hoc 
testing. *p < 0.05.  
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Figure 8. Signalling through p38 MAPK inhibits TNF- secretion that is 
reversed by inhibiting the PD-1 pathway in CD8+ T-cell subsets. (A and B) 
Secretion of TNF- by CD8+ CD45RA/CD27 subsets in young (A) and old (B) donors 
was measured by ELISA following 48 h stimulation with 0.5 g/ml anti-CD3 and 5 
g/ml IL-2 with either 10 g/ml anti-PDL1/2 block, 500 nM BIRB796 or both 
molecules. Graph shows the mean + SE for single measurements of 5 donors and P 
values were calculated a repeated measures ANOVA with the Tukey correction used 
for post-hoc testing.  *p < 0.05, **p < 0.01. 
 
 
